Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
CRNX Quote, Financials, Valuation and Earnings
Last price:
$48.77
Seasonality move
:
-13.46%
Day range:
$48.61 - $49.40
52-week range:
$24.10 - $54.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,965.64x
P/B ratio:
4.33x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
-9.43%
Market cap:
$4.6B
Revenue:
$1M
EPS (TTM):
-$4.53
Analysts' Opinion
-
Consensus RatingCrinetics Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $80.21, Crinetics Pharmaceuticals, Inc. has an estimated upside of 64.14% from its current price of $48.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing 100% downside risk from its current price of $48.87.
Fair Value
-
According to the consensus of 13 analysts, Crinetics Pharmaceuticals, Inc. has 64.14% upside to fair value with a price target of $80.21 per share.
CRNX vs. S&P 500
-
Over the past 5 trading days, Crinetics Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Crinetics Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Crinetics Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Crinetics Pharmaceuticals, Inc. reported revenues of $143K.
Earnings Growth
-
Crinetics Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Crinetics Pharmaceuticals, Inc. reported earnings per share of -$1.38.
Enterprise value:
3.6B
EV / Invested capital:
3.20x
Price / LTM sales:
2,965.64x
EV / EBIT:
--
EV / Revenue:
2,341.18x
PEG ratio (5yr expected):
-0.49x
EV / Free cash flow:
-10.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.1M
Return On Assets:
-32.49%
Net Income Margin (TTM):
-27563.32%
Return On Equity:
-37.41%
Return On Invested Capital:
-35.8%
Operating Margin:
-99710.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $709K | -- | $1.5M | -- | $143K | |
| Gross Profit | -$748K | -$2.3M | -$2.1M | -$770K | -$869K | |
| Operating Income | -$211.5M | -$307.8M | -$477.8M | -$87.8M | -$142.6M | |
| EBITDA | -$210.1M | -$305.5M | -$474.2M | -$87M | -$141.6M | |
| Diluted EPS | -$3.64 | -$3.72 | -$4.53 | -$0.96 | -$1.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204M | $378.3M | $575.8M | $877.6M | $1.1B | |
| Total Assets | $209.4M | $384.9M | $641.5M | $937.4M | $1.2B | |
| Current Liabilities | $12.4M | $24.6M | $40.5M | $53.6M | $74.2M | |
| Total Liabilities | $15.8M | $33.5M | $93.8M | $104.4M | $123.9M | |
| Total Equity | $193.6M | $351.4M | $547.7M | $833M | $1.1B | |
| Total Debt | $3.3M | $2.3M | $48.2M | $45.1M | $42.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$163M | -$199.8M | -$349.7M | -$62.8M | -$110.7M | |
| Cash From Investing | -$76.3M | -$120M | -$425.3M | $20.6M | $164.8M | |
| Cash From Financing | $351.1M | $494.3M | $568.6M | $57.3M | $3.1M | |
| Free Cash Flow | -$167M | -$203.6M | -$356M | -$63.4M | -$111.6M | |
CRNX
Sector
Market Cap
$4.6B
$28.1M
Price % of 52-Week High
89.21%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-14.42%
-1.49%
1-Year Price Total Return
-9.43%
-17.13%
Beta (5-Year)
0.200
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$48.42
200-day SMA
Buy
Level
$35.46
Bollinger Bands (100)
Buy
Level
32.99 - 46.11
Chaikin Money Flow
Buy
Level
3.7M
20-day SMA
Buy
Level
$47.38
Relative Strength Index (RSI14)
Buy
Level
58.27
ADX Line
Buy
Level
28.3
Williams %R
Neutral
Level
-26.5743
50-day SMA
Buy
Level
$44.47
MACD (12, 26)
Buy
Level
1.29
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
66.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.5987)
Sell
CA Score
(Annual)
Level (-0.4311)
Sell
Beneish M-Score
(Annual)
Level (15.6205)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.4587)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, CRNX has received 11 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CRNX average analyst price target in the past 3 months is $80.21.
-
Where Will Crinetics Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Crinetics Pharmaceuticals, Inc. share price will rise to $80.21 per share over the next 12 months.
-
What Do Analysts Say About Crinetics Pharmaceuticals, Inc.?
Analysts are divided on their view about Crinetics Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Crinetics Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Crinetics Pharmaceuticals, Inc.'s Price Target?
The price target for Crinetics Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $80.21 according to 13 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CRNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Crinetics Pharmaceuticals, Inc. is a Buy. 11 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRNX?
You can purchase shares of Crinetics Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Crinetics Pharmaceuticals, Inc. shares.
-
What Is The Crinetics Pharmaceuticals, Inc. Share Price Today?
Crinetics Pharmaceuticals, Inc. was last trading at $48.77 per share. This represents the most recent stock quote for Crinetics Pharmaceuticals, Inc.. Yesterday, Crinetics Pharmaceuticals, Inc. closed at $48.87 per share.
-
How To Buy Crinetics Pharmaceuticals, Inc. Stock Online?
In order to purchase Crinetics Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CRNX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRNX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.49x
-0.01x
P/B ratio
4.33x
1.81x
Price / LTM sales
2,965.64x
1.59x
Growth Metrics
CRNX
Sector
Revenue growth
158.4%
4.62%
Earnings growth
-43.94%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.25
-$0.21
Profitability
CRNX
Sector
Profitability FY 2024
-$1.7M
$3.6M
Return on invested capital
-35.8%
-31.84%
Return on assets
-32.49%
-27.96%
Return on equity
-37.41%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
CRNX
Sector
Total cash
$1.1B
$26.4M
Short term investments
$1.1B
$25.7M
Total assets
$1.7B
$76.9M
Long term debt
$42.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
